PMID- 24013990
OWN - NLM
STAT- MEDLINE
DCOM- 20160805
LR  - 20221207
IS  - 1530-891X (Print)
IS  - 1530-891X (Linking)
VI  - 20
IP  - 1
DP  - 2014 Jan
TI  - Real-world insulin treatment persistence among patients with type 2 diabetes.
PG  - 52-61
LID - 10.4158/EP13159.OR [doi]
AB  - OBJECTIVE: To evaluate real-world treatment persistence among patients with type 
      2 diabetes mellitus (T2DM) initiating treatment with insulin. METHODS: 
      Patient-level data were pooled from 3 previously published observational 
      retrospective studies evaluating patients with T2DM who were previously on oral 
      antidiabetic drugs (OADs) and initiated with a basal analog insulin (insulin 
      glargine or insulin detemir). Treatment persistence was defined as remaining on 
      the study drug during the 1-year follow-up period without discontinuation or 
      switching after study drug initiation. Analyses were conducted to identify 
      baseline factors associated with persistence with insulin therapy and to estimate 
      the association between insulin treatment persistence and patients' clinical and 
      economic outcomes during the follow-up period. RESULTS: A total of 4,804 patients 
      with T2DM (insulin glargine: n = 4,172, insulin detemir: n = 632) were included. 
      The average insulin persistence rate over the 1-year follow-up period was 65.0%. 
      A significantly higher persistence rate was associated with older age, initiation 
      with insulin glargine using either disposable pens or vial-and-syringe, and with 
      baseline exenatide or sitagliptin use. Higher insulin treatment persistence was 
      also associated with lower hemoglobin A1c (A1C) at follow-up, a greater reduction 
      in A1C from baseline, and lower health care utilization. CONCLUSION: In 
      real-world settings, treatment persistence among patients with T2DM initiating 
      basal insulin is influenced by the type of insulin and patient factors. Greater 
      insulin treatment persistence is linked to improved clinical outcomes and reduced 
      health care utilization.
FAU - Wei, Wenhui
AU  - Wei W
AD  - Sanofi U.S., Inc., Bridgewater, New Jersey.
FAU - Pan, Chunshen
AU  - Pan C
AD  - PRO Unlimited, Boca Raton, Florida.
FAU - Xie, Lin
AU  - Xie L
AD  - STATinMED Research, Inc., Ann Arbor, Michigan.
FAU - Baser, Onur
AU  - Baser O
AD  - University of Michigan, Ann Arbor, Michigan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
EDAT- 2013/09/10 06:00
MHDA- 2016/08/06 06:00
CRDT- 2013/09/10 06:00
PHST- 2013/09/10 06:00 [entrez]
PHST- 2013/09/10 06:00 [pubmed]
PHST- 2016/08/06 06:00 [medline]
AID - S1530-891X(20)43568-2 [pii]
AID - 10.4158/EP13159.OR [doi]
PST - ppublish
SO  - Endocr Pract. 2014 Jan;20(1):52-61. doi: 10.4158/EP13159.OR.